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Abstract
Background: The objective was to investigate in a group of obese subjects the course in skeletal
muscle phospholipid (SMPL) fatty acids (FA) during a 24-weeks weight maintenance program, which
was preceded by a successful very low calorie dietary intervention (VLCD). Special focus was
addressed to SMPL omega-3 FA, which is a lipid entity that influences insulin action.
Methods: Nine obese subjects (BMI = 35.7 ± 1.0 kg/m2), who had completed an 8 weeks VLCD
(weight-loss = -9.7 ± 1.6 kg, P < 0.001), had obtained skeletal muscle biopsies (vastus lateralis)
before and after a dietician-guided 24-weeks weight-maintenance program (-1.2 ± 1.5 kg, P = ns).
SMPL FA composition was determined by gas liquid chromatography. During the preceding VLCD,
insulin sensitivity (HOMA-IR) and glycemic control (HbA1c) improved but no change in SMPL
omega-3 FA was observed. During the weight-maintenance program five subjects received the
pancreas lipase inhibitor Orlistat 120 mg t.i.d. versus placebo.
Results: HOMA-IR and HbA1c stabilized and SMPL total omega-3 FA, docosahexaenoic acid and
ratio of n-3/n-6 polyunsaturated FA increased by 24% (P < 0.01), 35% (P < 0.02) and 26% (P < 0.01),
respectively, whereas saturated and monounsaturated FA did not change. Plasma total-cholesterol
and LDL-cholesterol, which decreased during the VLCD, reverted to pre-VLCD levels (P < 0.01).
Orlistat therapy was associated with weight-loss (P < 0.05), trends for better glycemic control (P
= 0.15) and greater increase in SMPL docosahexaenoic acid (P = 0.12) but similar reversal of plasma
cholesterols compared to placebo.
Conclusion: The data are consistent with the notion that greater SMPL omega-3 FA obtained
during a weight-maintenance program may play a role for preserving insulin sensitivity and glycemic
control being generated during a preceding VLCD.
Background
Very low calorie dietary intervention (VLCD) has proven
to be an efficient tool to provide weight-loss of 12 kg per
week in obese subjects [1]. VLCD is often carried out for 4
12 weeks, and, if successful in achieving a weight loss, is
likely to be associated with an improved lipid profile and
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insulin action [1-4]. It remains, however, a challenge to
stabilize or further improve the results obtained during a
VLCD both in terms of weight loss but also the metabolic
parameters associated with a reduced risk of co-morbidity
as cardiovascular disease and type 2 diabetes [1,4,5].
Intensified dietary advisory efforts after a VLCD may help
in accomplishing these goals, but at best a stabilization of
bodyweight may be achieved during this post-VLCD
period [1,4,5].
We have recently reported that during 8 weeks VLCD, in
which, as expected, plasma lipid profile and insulin sensi-
tivity improved significantly after weight loss, the phos-
pholipid fatty acid composition of the skeletal muscle cell
membrane also improved in terms of desaturation [3]. As
shown in several animal and human studies desaturation
of skeletal muscle phospholipids is associated with
improved insulin sensitivity [6-12]. However, improved
insulin action may especially be associated with long-
chain-polyunsaturated omega-3 fatty acids (LCPUFAn-3)
in the structural lipids of skeletal muscle and among the
LCPUFAn-3, docosahexaenoic acid (DHA) may be the
most important fatty acid (FA) in this context
[8,9,11,13,14]. We did not observe any net change in skel-
etal muscle phospholipid LCPUFAn-3 and especially
DHA did not increase during the 8 weeks VLCD [3], which
could be due to the longer retroconversion step of perox-
isomal -oxidation in DHA formation [15] and rapid turn-
over of whatever docosahexaenoic acid was present.
The present study aimed to investigate the changes in skel-
etal muscle phospholipid FA composition during a period
of weight stabilization following a successful VLCD in
obese subjects. To this end, we examined the subjects in
whom we previously reported desaturation in this lipid
entity during 8 weeks VLCD [3]. These subjects were fol-
lowed for an additional 24 weeks period of extensive die-
tary counseling and treatment with the pancreas lipase
inhibitor, Orlistat versus placebo [5]. We report that the
subjects during this period stabilized in weight and insu-
lin action concomitant with increased LCPUFAn-3 espe-
cially the DHA in their skeletal muscle membrane, which
coincided by a deterioration of their lipid profile to pre-
VLCD levels. It is suggested that improvement in struc-
tural lipids during a weight stabilizing period following
successful VLCD may help in preserving the improvement
in insulin action obtained during the preceding VLCD.
Methods
Study subjects
Seventeen obese volunteers (13 women) were recruited
from an ongoing dietary intervention study at our outpa-
tient university-based diabetes and obesity clinic. Thirteen
subjects (9 women) completed the 8 weeks VLCD and
consented to continue on the present study and have
obtained another muscle biopsy after 24 weeks on a die-
tary maintenance period. Data form the VLCD study has
been published previously [3]. Selection criteria at base-
line were abdominally obese patients (30 kg/m2 ≤ BMI <
40 kg/m2 and waist ≥ 92 cm (females) or waist ≥ 102 cm
(males)), of age ≥ 18 years and < 65 years and with at least
one of the following risk factors: a) early (i.e. only diet
treated) type 2 diabetes mellitus (fasting plasma glucose ≥
7 mM) or impaired fasting plasma glucose (6.1 mM ≤ FPG
< 7 mM); b) dyslipidemia, HDL-C ≤ 0.9 mM (males) or
HDL-C ≤ 1.1 mM (females) or serum triglycerides ≥ 2.3
mM but < 10 mM. Patients with a glycosylated hemo-
globin (HbA1c) > 10% were excluded. Any ongoing med-
ication for dyslipidemia and diabetes prohibited
participation in the study, as did supplements of n-3 fatty
acids (i.e. fish-oil), except from cod-oil in dietary doses.
Informed written consent was obtained in accordance
with Helsinki Declaration II. The local ethics committee
approved the present substudy and the study was
approved by the ethical committee of the cities of Copen-
hagen and Frederiksberg, Denmark (trial no. 01-363-98).
Dietary intervention and study medication
Recommended energy level during the VLCD period was
600  800 Kcal/day, which was provided by the Nutrilett
Intensive energy powder (Nycomed Pharma AS, Oslo,
Norway) [16]. The Nutrilett formula provides 318 Kcal
per 100 grams powder, i.e. proteins 36.8 grams, carbohy-
drates 30.7 grams and fatty acids 4.9 grams (1.3 gram sat-
urated fatty acids, 1.9 gram linoleic (C18:2 n-6), and 0.3
gram linolenic (C18:3 n-3) fatty acids). During the 24
weeks "weight maintenance" period the subjects were pre-
scribed a nutritionally balanced, hypocaloric diet
designed to cause weight loss of 0.25 to 0.50 kg/week,
with 30% of the calories as fat (optimally as 10% satu-
rated, 10% monounsaturated and 10% polyunsaturated),
50% carbohydrate and 20% protein. At the beginning of
the weight maintenance period subjects were also rand-
omized (doubled blinded, ratio 1:1) to receive either the
orally administered pancreas lipase inhibitor 120 mg t.i.d.
or corresponding placebo [5]. The subjects consulted a
registered dietician 6 times during the 8 weeks VLCD (i.e.
at weeks 0, 1, 3, 5, 7 and 8) and 10 times during the 24
weeks weight maintenance period (i.e. weeks 1, 2, 3, 4, 6,
8, 12, 16, 20, and 24) for the purpose of weight control
and guidance.
Anthropometric measurements
Body weight and height were measured on a calibrated
scale. Waist circumference was measured in the standing
position between the top of the iliac crest and the lower
rib margin on each side, while the patient exhaled, and
with the tape parallel to the floor. Hip circumference was
measured in the horizontal plane at the level of the maxi-
mal extension of the buttocks. Measurements of weight,Lipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
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height, waist, and hip were carried out in duplicate and
mean values were noted. BMI was calculated as weight/
height2 (kg/m2). Total body fat mass and lean body mass
were estimated by dual energy X-ray absorptiometry
(DEXA) scanning (Norland Medical System XR-36, Fort
Atkinson, WI, USA).
Blood sampling and assays
Blood samples were collected after an overnight fast (≥ 8
hours), handled and analyzed by commercial available
kits in accordance with the standard procedures for the
central laboratory, Medi-Lab (Copenhagen, Denmark).
The following blood variables were analyzed; HbA1c,
plasma glucose, plasma insulin, plasma C-peptide, total
cholesterol, HDL-cholesterol, LDL-cholesterol, and serum
triglyceride.
Muscle biopsy
A percutaneous muscle biopsy was obtained under local
anesthesia using a Bergström needle (Depuy, AZ, USA)
from the vastus lateralis muscle before and following the
8 weeks VLCD and after the 24 weeks weight maintenance
period. The specimen was immediately and carefully dis-
sected free of visible connective tissue, lipid and blood
and frozen in liquid nitrogen and stored at -80°C until
assayed.
Skeletal muscle phospholipids and triglycerides
Extraction of skeletal muscle phospholipids and triglycer-
ides in general followed the principle described by Folch
et al [17]. Internal standards of C15:0 phosphatidylcho-
line and C15:0 triglycerides were added to samples of
skeletal muscle tissue followed by extraction of the total
lipid material with chloroform/methanol, 2:1, vol/vol,
after homogenization with an Ultra Turrax homogenizer.
The extracted lipids were separated into phospholipids
and triglycerides by thinlayer chromatography (TLC)
using a pre-manufactured silica plate (E. Merck, Ger-
many). The kiesel gel bands containing the phospholipids
and the triglycerides were scraped off the TLC plate and
the lipids were extracted from the kiesel gel. The fatty acid
profiles of phospholipids and triglycerides were deter-
mined by gas-liquid chromatography (GLC) of the fatty
acid methyl esters using a Hewlett-Packard 6890 instru-
ment (Hewlett-Packard, Germany) equipped with an
SP2380 capillary column (60 m × 0.25 mm, ID, and film
thickness 0.2 μm, Supelco, PA, USA) operated with tem-
perature programming and using helium as carrier gas.
Detection was by flameionisation. Fatty acids methylest-
ers were identified by comparing their retention times
with those of actual standards (Sigma Inc., MO, USA). The
individual fatty acids were quantified and reported as
their percentage of the total peak area. Only fatty acids
constituting more than 0.1% of total peak area are
reported. Content of triglycerides in each sample was cal-
culated from the internal standard.
Calculations
The homeostasis model assessment insulin resistance
index (HOMA-IR) derives an estimate of whole body
insulin sensitivity from fasting glucose and insulin con-
centrations [18]. Changes, when given in percentages,
were calculated as the value after the intervention period
minus the value before the intervention period divided by
the latter value and multiplied with 100%.
Statistics
All data are presented as mean ± SEM if not otherwise
indicated. The paired student t-test was used to compare
distribution of paired data sets. Statistical analyses were
performed using SPSS version 12.0 (SPSS Inc., IL, USA).
Statistical significance was accepted for P < 0.05.
Results
Data are shown for the nine obese subjects (seven
women) who had obtained skeletal muscle biopsy at the
end of the preceding 8 weeks VLCD and after 24 weeks on
a weight stabilization diet (Table 1). Thus four subjects
out of the initial 13 subjects who had taken the biopsy
after the VLCD period missed the final biopsy, which was
due to unwillingness to undertake this procedure. There
was no difference in baseline parameters among those
who had taken a biopsy during the weight maintenance
period and those who had not.
The subjects succeeded in stabilizing body weight, fasting
plasma glucose, insulin, HbA1c, C-peptide and HOMA-IR
during the weight maintenance period, whereas plasma
lipids reverted to pre-VLCD levels (Table 1). Among the
nine subjects who fulfilled this study, five subjects (four
women) received the pancreas lipase inhibitor, Orlistat
120 mg t.i.d. The changes in bodyweight among the sub-
jects on Orlistat compared to those on placebo showed
that the former lost more weight (-3.9 kg vs. +2.2 kg, P <
0.05) and the Orlistat group also showed a trend for better
glycemic control (HbA1c -0.1% vs. +0.2%, P = 0.15), but
both sub-groups showed the same reversal of plasma cho-
lesterols and plasma triglyceride towards pre-VLCD levels
(data not shown).
Table 2 shows the changes in FA composition of skeletal
muscle phospholipids during the 24 weeks weight main-
tenance period following the 8 weeks VLCD, pre-VLCD
data are also given for comparison. Notable, the concen-
tration of LCPUFAn-3 increased considerable due to
increased DHA and EPA (eicosapentaenoic acid) and the
ratio of LCPUFA n-3/n-6 increased (Figure 1). The precur-
sor of LCPUFAn-3, α-linolenic acid (C18:3n-3) increased.
No net changes in saturated or monounsaturated FA were
observed during the 24 weeks period of weight mainte-
nance. However, if we consider the pre-VLCD concentra-
tion of total saturated FA through to the weight
maintenance period it decreased by 7.6%, P < 0.05. ThereLipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
Page 4 of 10
(page number not for citation purposes)
was a trend for a greater effect on DHA in the Orlistat
group compared to placebo (51% vs. 17%, P = 0.12) but
no trends for differences in EPA (34% vs. 32%) or total
LCPUFAn-3 (31% vs.14%).
Table 3 shows the changes in intramyocellular triglyceride
FA composition and total content of this depot lipid. Con-
tent of intramyocellular triglyceride decreased insignifi-
cantly by 2.3 mg/g wet tissue weight during the weight
maintenance period. By including the VLCD period the
total decrease in IMTG was 5.0 mg/g wet tissue weight (-
24%, P = 0.15). During the 24 weeks weight maintenance
period the general picture of changes in FA of intramyo-
cellular lipid was a reduction in LCPUFAn-6 by 35%, P <
0.05 and LCPUFAn-3 by 64%, P < 0.01, whereas total
monounsaturated FA showed a trend for increase of 2.0%,
P = 0.07 and total saturated FA were unchanged. There
were no trends towards a difference in effect on amount
Table 1: Anthropometric and metabolic characteristics of study subjects after VLCD and during the weight maintenance period
After VLCD During weight maintenance Before VLCD
Mean SEM Mean SEM % change P Mean
Age (years) 52.4 3.3 52.8 3.3 52.2
Height (cm) 171.1 3.3
BMI (kg/m2) 32.4 1.1 31.9 1.4 -1.3 ns 35.7*
Waist (cm) 104.3 1.5 103.3 2.5 -1.0 ns 111.3*
Hip (cm) 117.6 3.4 117.4 4.4 -0.1 ns 124.4*
Fat mass (kg) 38.5 3.8 35.8 4.1 -7.0 ns 44.8*
Lean mass (kg) 53.2 4.4 55.2 4.0 3.8 ns 56*
Weight (kg) 94.7 4.0 93.5 4.9 -1.3 ns 104.5*
Fp-glucose (mM) 6.2 0.2 6.5 0.2 6.0 ns 7.5*
Fp-insulin (pM) 57 6 69 9 20.4 ns 86*
Fp-C-peptide (pM) 841 87 878 88 4.4 ns 1084*
HbA1c (%) 6.1 0.2 6.1 0.2 0.3 ns 6.7*
HOMA-IR 2.2 0.3 2.8 0.5 28.9 ns 4.1*
Fp-cholesterol (mM) 5.2 0.4 6.4 0.4 22.1 <0.001 6.4*
Fp-LDL-cholesterol (mM) 3.3 0.4 4.0 0.3 19.0 <0.01 4.2*
Fp-HDL-cholesterol (mM) 1.2 0.1 1.4 0.1 10.8 <0.05 1.4*
Fs-triglyceride (mM) 1.4 0.1 2.2 0.4 55.8 ns 1.8
Data are from n = 9 subjects (7 females). For comparison data from before the VLCD are given for these subjects. Asterisks indicate P < 0.05 for 
comparison between "before" and "after" the preceding VLCD.
"% change" indicates the change relative to baseline level (i.e. after VLCD); BMI, body mass index; Fp, fasting plasma,; HbA1c, glycosylated 
hemoglobin; HOMA-IR, homeostasis model assessment; Fs, fasting serumLipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
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and composition of intramyocellular triglyceride between
those who were treated with Orlistat compared to those
on placebo (data not shown).
Discussion
The major finding in the present pilot study on the fatty
acid composition of structural lipids of skeletal muscle
membrane in obese subjects during a weight stabilization
period after a successful VLCD was that the important
LCPUFAn-3 docosahexaenoic acid (DHA) and eicosapen-
taenoic acid (EPA) increased. This improvement obtained
in FA composition of structural lipids during the weight
stabilizing period after a VLCD may have provided assist-
ance to preserve insulin action and glycemic control in
face of reversal of plasma lipids to pre-VLCD levels. The
data also provide some evidence to suggest that the posi-
tive effect of a pancreas lipase inhibitor as Orlistat on
body weight in the post-VLCD period may be associated
with a beneficial effect on the FA composition of skeletal
muscle structural lipids.
VLCD has proven to be effective in the short run, whereas
the post-VLCD period has been a period of massive failure
to simply just maintain the achieved weight loss [1]. In
this perspective close dietary advisory efforts may be of
importance, but also anti-obesity medication may help in
stabilizing body weight and may even facilitate further
weight loss [1,5]. The pancreas lipase inhibitor Orlistat
has proven an effective tool to achieve a surplus of weight
loss compared to placebo in studies where all obese sub-
jects were undergoing dietary guidance concomitant with
anti-obesity medication [19]. Orlistat reduces the absorp-
tion of fat, including saturated fat from the intestinal with
about 30%.
The present study aimed to obtain new knowledge about
the changes in FA composition of phospholipids of skele-
tal muscle membrane during the setting of a post-VLCD
period. Skeletal muscle is the major site of insulin action
in terms of facilitating glucose metabolism. The FA com-
position of the skeletal muscle cell membrane is associ-
ated with insulin action such that a lower saturation and
a higher concentration of LCPUFAn-3 facilitate insulin
action [6,8-10,12,13,20-23]. The mechanism may involve
changes in number of insulin receptors and facilitated
insulin signal transduction in the skeletal muscle cell
[7,14,24]. The phospholipid FA composition may be
modified during moderate weight loss over 24 weeks as
previously shown by us [9]. Thus, changes in LCPUFAn-3
especially the DHA of this lipid entity may confer
The four diagrams show the key-changes in skeletal muscle phospholipid fatty acid composition during a period of weight stabi- lization following a VLCD Figure 1
The four diagrams show the key-changes in skeletal muscle phospholipid fatty acid composition during a 
period of weight stabilization following a VLCD. Concentration of long-chain polyunsaturated fatty acids of the n-3 class 
(LCPUFAn-3) increased due to increased eicosapentaenoic acid (EPA, C20:5n-3) and docosahexaenoic acid (DHA, C22:6n-3); 
also the ratio of LCPUFA of the n-3 class versus the n-6 class increased. Data are Mean +/- SEM. White bars give data obtained 
at the end of the VLCD period (baseline) and black bars give data obtained 24 weeks later during the weight maintenance 
period. *, P < 0.05; **, P < 0.01.
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Table 2: Skeletal muscle phospholipids of study subjects after VLCD and during the weight maintenance period
After VLCD During weight maintenance Before VLCD
Mean SEM Mean SEM % change P Mean
C14:0 0.41 0.02 0.53 0.04 28.8 <0.05 0.47
C16:0 16.63 0.83 16.23 0.45 -2.4 ns 17.93
C18:0 17.71 0.37 16.79 0.28 -5.2 ns 18.05
Saturated 35.01 0.69 33.96 0.36 -3.0 ns 36.73*
C16:1(n-7) 0.79 0.05 0.77 0.09 -2.5 ns 0.76
C18:1trans 0.53 0.09 0.75 0.11 41.8 ns 0.51
C18:1(n-9) 7.99 0.31 7.21 0.42 -9.7 ns 7.69
C18:1(n-7) 2.34 0.11 2.17 0.10 -7.2 <0.05 2.16*
Monounsaturated 11.88 0.40 11.19 0.59 -5.9 ns 11.27*
C18:2(n-6) 30.93 0.92 31.89 1.38 3.1 ns 31.75
C18:3(n-3) 0.31 0.05 0.46 0.04 48.0 <0.05 0.40
C20:3(n-9) 0.28 0.01 0.21 0.02 -23.2 ns 0.23
C20:3(n-6) 1.42 0.09 1.38 0.11 -2.9 ns 1.40
C20:4(n-6) 13.64 0.59 12.67 0.62 -7.1 ns 12.04*
C20:5(n-3) 0.86 0.12 1.13 0.16 31.6 <0.01 1.02*
C22:4(n-6) 0.54 0.09 0.48 0.03 -11.6 ns 0.42*
C22:5(n-3) 1.26 0.10 1.26 0.14 0.0 ns 1.08
C22:6(n-3) 2.08 0.22 2.81 0.40 35.1 <0.05 2.15
PUFA 51.13 0.80 52.27 0.97 2.2 ns 50.35
LCPUFA 20.31 0.67 20.24 1.11 -0.3 ns 18.54
LCPUFAn-3 4.20 0.41 5.20 0.65 23.8 <0.05 4.25
LCPUFAn-6 15.70 0.65 14.64 0.73 -6.7 ns 13.94*
Ratio LCPUFA n-3/n-6 0.098 0.012 0.124 0.017 25.8 <0.01 0.104
Data are from n = 9 subjects (7 females). For comparison data from before the VLCD are given for these subjects. Asterisks indicate P < 0.05 for 
comparison between "before" and "after" the preceding VLCD.
"% change" indicates the change relative to baseline level (i.e. after VLCD); FA, fatty acids; PUFA, polyunsaturated fatty acids; LCPUFA, long chain 
(i.e. ≥ C20) polyunsaturated fatty acids;Lipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
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Table 3: Skeletal muscle triglycerides of study subjects after VLCD and during the weight maintenance period
After VLCD During weight maintenance Before VLCD
Mean SEM Mean SEM % change P Mean
C12:0 0.64 0.11 0.66 0.13 3.5 ns 0.62
C14:0 2.70 0.15 2.96 0.19 9.6 <0.05 2.80
C16:0 22.72 0.46 23.64 0.44 4.0 <0.05 23.56
C18:0 4.28 0.45 3.73 0.29 -12.8 ns 4.15
Saturated 30.55 0.97 31.21 0.86 2.2 ns 31.34
C14:1 0.41 0.04 0.47 0.05 16.1 <0.05 0.35
C16:1(n-9) 0.72 0.05 0.79 0.06 9.5 <0.05 1.02
C16:1(n-7) 5.56 0.53 6.52 0.48 17.3 <0.01 5.74
C18:1trans 1.19 0.08 1.23 0.13 3.0 ns 1.03
C18:1(n-9) 43.18 0.48 43.49 0.56 0.7 ns 42.73
C18:1(n-7) 2.63 0.12 2.56 0.11 -2.7 ns 2.98
C20:1 0.91 0.02 0.60 0.03 -34.7 <0.01 0.66
Monounsaturated 54.90 0.81 55.99 0.60 2.0 ns 54.72
C18:2(n-6) 10.86 0.32 10.40 0.34 -4.2 <0.05 10.81
C18:3(n-3) 1.04 0.10 1.00 0.10 -3.9 ns 1.11
C20:3(n-6) 0.26 0.02 0.19 0.03 -27.6 ns 0.21
C20:4(n-6) 0.49 0.04 0.40 0.06 -18.0 ns 0.36*
C22:3(n-3) 0.39 0.09 0.04 0.04 -89.8 <0.01 0.31
C22:5(n-3) 0.46 0.04 0.21 0.08 -54.7 <0.01 0.35*
C22:6(n-3) 0.55 0.12 0.31 0.14 -43.3 <0.05 0.46
PUFA 14.21 0.49 12.56 0.58 -11.6 <0.01 13.73
LCPUFA 2.45 0.24 1.37 0.29 -44.2 <0.01 1.86*
LCPUFAn-3 1.44 0.21 0.52 0.22 -64.3 <0.01 1.16*Lipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
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improved insulin sensitivity [9]. As shown previously, the
8 weeks VLCD did not improve LCPUFAn-3 in skeletal
muscle cell membrane [3]. This was speculated to be
caused by a longer retroconversion step of peroxisomal -
oxidation in DHA formation [15] or increased usage of
the muscle cell membrane DHA.
The present study suggests that adherence to a diet over 24
weeks, which is able to stabilize a fast obtained weight
loss during a VLCD, may further improve the FA compo-
sition of phospholipids in skeletal muscle of obese sub-
jects. Whereas the preceding 8 weeks VLCD was associated
with a reduction in saturated FA and increased monoun-
saturated FA contents, only changes in the LCPUFAn-6
class (increase) and not the LCPUFAn-3 class were
obtained during this preceding VLCD. During the subse-
quent 24 weeks on a weight stabilizing diet, the contents
of the class of LCPUFAn-3 increased, which was primarily
due to the fact that both DHA and EPA increased during
this period. DHA and EPA in cell membrane phospholip-
ids have been associated with improved insulin action
[11,13,25]. The ratio of n-3/n-6 LCPUFA also increased
during this period, which may further indicate a more
"healthy" muscle membrane in terms of a FA composition
likely to facilitate insulin action. The magnitude of
improvement of LCPUFAn-3, especially the increase in
DHA and the ratio of LCPUFA n-3 vs. n-6 may translate
into a relative improvement in insulin sensitivity of
approximately 25% given the results from other studies as
discussed previously [26]. Of note, no further improve-
ment in saturated or monounsaturated FA was obtained
during the 24 weeks of stable body weight after a VLCD,
but throughout the total period of VLCD and weight
maintenance the saturated FA of structural lipids
decreased, which may also have aided in improving glu-
cose metabolism [9]. The mechanisms behind the
improved skeletal muscle phospholipid FA profile in this
setting could be several. It may be that the preceding
VLCD did not reveal an increased concentration of DHA
due to the complex and longer duration of DHA forma-
tion [15]. A sustained dietary restriction program may
increase level of LCPUFAn-3 as shown in the rat model
[27]. Indeed, the changes in dietary FA composition dur-
ing the weight maintenance period may have conferred
the observed changes in the structural lipids FA composi-
tion of these obese subjects [8,9,11,28,29]. The results
also support that the dietary source of LCPUFAn-3 had
been indirect through providing increased amount of die-
tary linolenic acid, which could be elongated and desatu-
rated in situ to EPA and DHA. Thus, the study provides an
example of dissociation between effects of diet restriction
on skeletal muscle structural lipid composition and
weight loss per se in obese humans.
In accordance with the known effects of Orlistat on weight
reduction and maintenance, we observed a significant dif-
ference in changes in weight during the 24 weeks post-
VLCD between those treated with Orlitat versus placebo
in our relatively small study population [5,19]. Accord-
ingly, we cannot exclude the possibility that the trend
towards a superior effect of Orlistat on the composition of
the structural lipids to some extent may be due to a greater
loss of body weight in the Orlistat arm. Nevertheless, this
small pilot study obviously was not designed to address
this aspect of Orlistat treatment, which needs to be
addressed in a separate study.
A high amount of intramyocellular triglycerides in seden-
tary subjects has been associated with insulin resistance
[30-34]. Taken together, the VLCD intervention followed
by the 24 weeks weight maintenance period in the present
study showed a trend for a 24% decline in intramyocellu-
lar triglycerides. Interestingly, the changes in the FA com-
position in intramyocellular triglyceride went opposite as
compared to the changes in FA in phospholipids during
the 24 weeks weight maintenance period. Thus the con-
tents of LCPUFAn-3 and LCPUFAn-6 decreased in
intramyocellular triglyceride. It should be acknowledged,
however, that whereas the data to support an impact of
the skeletal muscle FA composition on insulin action
seems strong and consistent, the data to suggest an effect
of the intramyocellular triglyceride FA composition play-
ing some role for glucose metabolic parameters are scarce
and contradicting [12,35-38]. Nevertheless, the obviously
opposite net effect on the FA composition of intramyocel-
lular triglyceride versus skeletal muscle phospholipids
suggest different metabolism of these lipid entities, at
least when evaluated during a dynamic setting after a
VLCD.
LCPUFAn-6 1.00 0.07 0.65 0.11 -35.1 <0.05 0.70*
Total IMTG (mg/g wet tissue) 18.4 4.6 16.1 2.1 -12.5 ns 21.1
Data are from n = 9 subjects (7 females). For comparison data from before the VLCD are given for these subjects. Asterisks indicate P < 0.05 for 
comparison between "before" and "after" the preceding VLCD.
"% change" indicates the change relative to baseline level (i.e. after VLCD); FA, fatty acids; PUFA, polyunsaturated fatty acids; LCPUFA, long chain 
(i.e. ≥ C20) polyunsaturated fatty acids; IMTG, intramyocellular triglyceride
Table 3: Skeletal muscle triglycerides of study subjects after VLCD and during the weight maintenance period (Continued)Lipids in Health and Disease 2009, 8:34 http://www.lipidworld.com/content/8/1/34
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Conclusion
Considering the caveats of a small pilot study such as this,
the present data suggest that following a successful 8
weeks VLCD, a 24 weeks period of weight maintenance
program including the pancreas lipase inhibitor Orlistate
may be associated with improvements in the FA composi-
tion of skeletal muscle phospholipids in terms of signifi-
cant increases in EPA and DHA, which potentially may
help in stabilizing insulin sensitivity in this setting.
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